Web-Based Tool Designed to Improve Quality of Care in Thyroid Cancer
The Thyroid Cancer Clinical Registry is expected to improve quality of patient care as patient data would be readily available to all physicians involved in the patients care; however former Commission on Cancer chair Frederick L Greene, MD, wonders whether physicians would take the time to enter the clinical data into the system as required.
Delayed HCV Treatment in Coinfected Patients Can Prove Fatal
Modeling data discussed at a press conference at the 2015 Conference on Retroviruses and Opportunistic Infections showed that delaying HCV treatment, consequent to the high cost of the newer antiviral regimens, could prove fatal in patients coninfected with HIV.
Despite Increased Health Data Breaches, Fines Remain Rare
In a string of meetings and press releases, the federal government's health watchdogs have delivered a stern message: They are cracking down on insurers, hospitals, and doctors offices that don't adequately protect the security and privacy of medical records.
Study on Chronic Fatigue May Help With Diagnoses
The immune systems of people with chronic fatigue syndrome differ from those of healthy people, and patients with recent diagnoses can be distinguished from those who have had the condition for longer, according to researchers.
Urine Test for Bladder Cancer Could Aid Early Detection
A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.
Managed Care Minute: February 28, 2015
A one-minute look at managed care news during the week of February 23, 2015, including another step by CMS toward a quality-based payment system and more predictions on the outcomes of King v. Burwell
Opdivo Gets Priority Review for NSCLC
BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.
AJMC Panel Sees Advantages in FDA Regulation of Molecular Diagnostic Tests for Cancer CareThe American Journal of Managed Care
convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA’s plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.
For Stakeholders in Immuno-Oncology, Is the Third Time the Charm?Evidence-Based Oncology
, an indexed publication of The American Journal of Managed Care
, devotes its current issue to immuno-oncology and the interests of many stakeholders. In a commentary that draws on 30 years of waiting on the promise of immuno-oncology, Bruce Feinberg, DO, outlines the key issues facing payers, oncologists, policymakers and patients themselves.
Basket Trials Have FDA Support, But Will They Deliver?
Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.